Now speaking at Global Voices in Renal Oncology (VIRO) 2025 organized by OncoDaily: Dr. Yu-Wei Chen, Assistant Professor of Medicine and Medical Oncologist at UC San Diego Health, on the topic “Integration of HIF2a inhibition in RCC”.
Dr. Chen outlined the rapidly evolving role of HIF-2α inhibitors in renal cell carcinoma (RCC), emphasizing their impact across VHL-associated tumors, refractory disease, and in novel combination strategies.
He began by reviewing the biological foundation: the VHL-HIF pathway is central to oxygen sensing and tumor growth in RCC, with VHL alterations present in up to 90% of clear cell tumors. The landmark LITESPARK-004 trial demonstrated that belzutifan achieved a 70% response rate in VHL-associated RCC with durable responses extending beyond four years. Equally strong activity was seen in pancreatic neuroendocrine tumors and CNS hemangioblastomas, leading to FDA approval of belzutifan for VHL disease–associated cancers.
Join us in this conversation.